187 related articles for article (PubMed ID: 34589965)
1. Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1-Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms.
Szlosarek PW; Phillips MM; Pavlyk I; Steele J; Shamash J; Spicer J; Kumar S; Pacey S; Feng X; Johnston A; Bomalaski J; Moir G; Lau K; Ellis S; Sheaff M
JTO Clin Res Rep; 2020 Nov; 1(4):100093. PubMed ID: 34589965
[TBL] [Abstract][Full Text] [Related]
2. Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer.
Szlosarek PW; Wimalasingham AG; Phillips MM; Hall PE; Chan PY; Conibear J; Lim L; Rashid S; Steele J; Wells P; Shiu CF; Kuo CL; Feng X; Johnston A; Bomalaski J; Ellis S; Grantham M; Sheaff M
Cancer Med; 2021 Oct; 10(19):6642-6652. PubMed ID: 34382365
[TBL] [Abstract][Full Text] [Related]
3. A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Phillips MM; Pavlyk I; Allen M; Ghazaly E; Cutts R; Carpentier J; Berry JS; Nattress C; Feng S; Hallden G; Chelala C; Bomalaski J; Steele J; Sheaff M; Balkwill F; Szlosarek PW
Pharmacol Rep; 2023 Jun; 75(3):570-584. PubMed ID: 37010783
[TBL] [Abstract][Full Text] [Related]
4. A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma.
Hall PE; Lewis R; Syed N; Shaffer R; Evanson J; Ellis S; Williams M; Feng X; Johnston A; Thomson JA; Harris FP; Jena R; Matys T; Jefferies S; Smith K; Wu BW; Bomalaski JS; Crook T; O'Neill K; Paraskevopoulos D; Khadeir RS; Sheaff M; Pacey S; Plowman PN; Szlosarek PW
Clin Cancer Res; 2019 May; 25(9):2708-2716. PubMed ID: 30796035
[TBL] [Abstract][Full Text] [Related]
5. A Phase 1 study of ADI-PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1-negative metastatic uveal melanoma.
Chan PY; Phillips MM; Ellis S; Johnston A; Feng X; Arora A; Hay G; Cohen VML; Sagoo MS; Bomalaski JS; Sheaff MT; Szlosarek PW
Pigment Cell Melanoma Res; 2022 Jul; 35(4):461-470. PubMed ID: 35466524
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.
Beddowes E; Spicer J; Chan PY; Khadeir R; Corbacho JG; Repana D; Steele JP; Schmid P; Szyszko T; Cook G; Diaz M; Feng X; Johnston A; Thomson J; Sheaff M; Wu BW; Bomalaski J; Pacey S; Szlosarek PW
J Clin Oncol; 2017 Jun; 35(16):1778-1785. PubMed ID: 28388291
[TBL] [Abstract][Full Text] [Related]
7. Role of 3'-Deoxy-3'-[
Szyszko TA; Dunn JT; Phillips MM; Bomalaski J; Sheaff MT; Ellis S; Pike L; Goh V; Cook GJR; Szlosarek PW
JTO Clin Res Rep; 2022 Sep; 3(9):100382. PubMed ID: 36082278
[TBL] [Abstract][Full Text] [Related]
8. Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.
Szlosarek PW; Steele JP; Nolan L; Gilligan D; Taylor P; Spicer J; Lind M; Mitra S; Shamash J; Phillips MM; Luong P; Payne S; Hillman P; Ellis S; Szyszko T; Dancey G; Butcher L; Beck S; Avril NE; Thomson J; Johnston A; Tomsa M; Lawrence C; Schmid P; Crook T; Wu BW; Bomalaski JS; Lemoine N; Sheaff MT; Rudd RM; Fennell D; Hackshaw A
JAMA Oncol; 2017 Jan; 3(1):58-66. PubMed ID: 27584578
[TBL] [Abstract][Full Text] [Related]
9. Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.
Szlosarek PW; Creelan BC; Sarkodie T; Nolan L; Taylor P; Olevsky O; Grosso F; Cortinovis D; Chitnis M; Roy A; Gilligan D; Kindler H; Papadatos-Pastos D; Ceresoli GL; Mansfield AS; Tsao A; O'Byrne KJ; Nowak AK; Steele J; Sheaff M; Shiu CF; Kuo CL; Johnston A; Bomalaski J; Zauderer MG; Fennell DA;
JAMA Oncol; 2024 Apr; 10(4):475-483. PubMed ID: 38358753
[TBL] [Abstract][Full Text] [Related]
10. Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer.
Hall PE; Ready N; Johnston A; Bomalaski JS; Venhaus RR; Sheaff M; Krug L; Szlosarek PW
Clin Lung Cancer; 2020 Nov; 21(6):527-533. PubMed ID: 32859536
[TBL] [Abstract][Full Text] [Related]
11. Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers.
Chang KY; Chiang NJ; Wu SY; Yen CJ; Chen SH; Yeh YM; Li CF; Feng X; Wu K; Johnston A; Bomalaski JS; Wu BW; Gao J; Subudhi SK; Kaseb AO; Blando JM; Yadav SS; Szlosarek PW; Chen LT
Oncoimmunology; 2021; 10(1):1943253. PubMed ID: 34290906
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.
McAlpine JA; Lu HT; Wu KC; Knowles SK; Thomson JA
BMC Cancer; 2014 Aug; 14():621. PubMed ID: 25164070
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 trial of ADI-PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors.
Yao S; Janku F; Koenig K; Tsimberidou AM; Piha-Paul SA; Shi N; Stewart J; Johnston A; Bomalaski J; Meric-Bernstam F; Fu S
Cancer Med; 2022 Jan; 11(2):340-347. PubMed ID: 34841717
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies.
Harding JJ; Do RK; Dika IE; Hollywood E; Uhlitskykh K; Valentino E; Wan P; Hamilton C; Feng X; Johnston A; Bomalaski J; Li CF; O'Reilly EM; Abou-Alfa GK
Cancer Chemother Pharmacol; 2018 Sep; 82(3):429-440. PubMed ID: 29971467
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
Nakagawa K; Yamazaki K; Kunitoh H; Hida T; Gemba K; Shinkai T; Ichinose Y; Adachi S; Nambu Y; Saijo N; Fukuoka M
Jpn J Clin Oncol; 2008 May; 38(5):339-46. PubMed ID: 18434338
[TBL] [Abstract][Full Text] [Related]
16. JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma.
Miyamoto Y; Kozuki T; Aoe K; Wada S; Harada D; Yoshida M; Sakurai J; Hotta K; Fujimoto N
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34711664
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
Tsao AS; Harun N; Lee JJ; Heymach J; Pisters K; Hong WK; Fujimoto J; Wistuba I
Clin Lung Cancer; 2014 May; 15(3):197-201. PubMed ID: 24492162
[TBL] [Abstract][Full Text] [Related]
18. Argininosuccinate Synthetase-1 (ASS1) Loss in High-Grade Neuroendocrine Carcinomas of the Urinary Bladder: Implications for Targeted Therapy with ADI-PEG 20.
Gupta S; Sahu D; Bomalaski JS; Frank I; Boorjian SA; Thapa P; Cheville JC; Hansel DE
Endocr Pathol; 2018 Sep; 29(3):236-241. PubMed ID: 29453600
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study.
Nakano T; Kuribayashi K; Kondo M; Morise M; Tada Y; Hirano K; Hayashi M; Tanaka M; Hirabayashi M
Asia Pac J Clin Oncol; 2021 Jun; 17(3):264-272. PubMed ID: 32893992
[TBL] [Abstract][Full Text] [Related]
20. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
